Japan could become one of the first countries in the world to end the HIV epidemic, says the president of Gilead Sciences Japan, Kennet Brysting. The idea for now could seem a little too ambitious, but it is not entirely unrealistic, given that the availability of medicines that can prevent transmission of HIV. Drugs are not the cure, but control over the spread of virus to the point where the disease is no longer a major public health threat.

What Is The Role Of Preventative HIV Medicines?

Gilead's have two key drugs, Truvada and lenacapavir. These two are playing a crucial role in prevention. Truvada is taken as a daily pill, while lenacapavir requires two injections per year. It can make the virus undetectable in infected individuals and prevent transmission to those who are not infected yet. In trials, lenacapavir showed 100% efficacy in preventing HIV infections. This is why it is describe as "almost a vaccine".

In 2024, Japan also approved Truvada for HIV prevention, but the country has yet to approve lenacapavir for the same. Until now, people in Japan had been importing generic versions of Truvada or purchasing it from clinics that source it from overseas.

HIV In Japan

Up until now, Japan reported around 25,000 HIV infections, whereas 669 new cases were reported in 2023. For seven consecutive years, the number of new infections remained under 1,000. The downward trend thus shows that the virus has been controlled, however, getting to zero new infections remains the ultimate goal.

Brysting too acknowledged that simply having effective drug is not enough. What is important is to have a proper implementation, access and healthcare support to make sure that these treatments are widely available and effective.

What Are The Challenges In Implementation?

The biggest challenges is testing rates. There is a need to increase testing rates. At this very moment, around 86% people infective with Japan have been tested, but the goal is to increase it up to 95%, with an ideal goal of 100%. Without widespread testing, many infected people may not even know that they are infected and it could transmit the virus.

Another measure issue is the cost of preventative medication. While Japan's health insurance covers treatments for diseases, it does not cover preventative drugs. Those who purchase Truvada for prevention, pay around $470 per month. Some clinics in Tokyo offer generic alternatives too, which is cheaper, but they are not ideal.

Better Healthcare Support

Brysting expressed concern that individuals importing medications might not be consulting doctors regularly, which is essential for monitoring HIV status and overall health. Truvada users need to be tested for HIV initially and every three months, along with screenings for other infections and kidney function checks. Without proper medical supervision, there is a risk of misuse and inadequate protection.

Gilead is in discussions with Japanese authorities to improve access and insurance coverage for Truvada, and progress is being made. Japan has shown efficiency in approving critical medicines, as seen during the COVID-19 pandemic when Gilead’s remdesivir was approved in just three days.

What Is The Way Ahead?

Gilead at this moment is not only focused on HIV and hepatitis C, but also expanding into oncology with innovative treatments like CAR-T cell therapy, which strengthens a patient's immune system to fight cancer.

However, Japan’s strict approval processes can slow down drug availability. Phase 3 clinical trials often need to be conducted within the country, and Japan tends to approve medicines much later than other regions. For instance, Truvada was approved for prevention in Japan 12 years after the U.S. and nearly 20 years after its approval for treatment. inancial factors also play a role. The Japanese government adjusts drug prices annually, often reducing them, which can make long-term investment challenging for pharmaceutical companies.

Developed by the US-based late-stage clinical oncology company Revolution Medicines, daxaronrasib has shown promise in improving survival rates among patients with metastatic pancreatic ductal adenocarcinoma (PDAC).

In a clinical trial, daxaronrasib demonstrated a median overall survival of 13.2 months, compared with 6.7 months for standard chemotherapy.

Experts believe the drug may also prove effective against other cancers, including cancerous tumors in lung and ovaries.

The drug works by targeting mutations in the KRAS gene, which are found across multiple cancer types, including lung, colorectal, ovarian, endometrial and a type of bile duct cancer known as cholangiocarcinoma.

“Daxaronrasib provides a clear and highly meaningful step forward for patients with pancreatic cancer who have experienced progression on prior treatment, typically chemotherapy,” said Brian M. Wolpin, professor of medicine at Harvard Medical School and principal investigator of the trial.

“Pancreas cancer may be the first for this drug, but there will be others,” he added, noting that “Now the floodgates open.”

What Is Daxaronrasib? How Does It Work?

Also read: Former US Senator Ben Sasse Opens Up About Battle With Terminal Stage 4 Pancreatic Cancer

Daxaronrasib is a daily oral pill that has demonstrated statistically significant and clinically meaningful improvements in progression-free survival (PFS) and overall survival (OS) compared with standard intravenous chemotherapy.

Described as a multi-selective inhibitor of RAS(ON) proteins, it is the first investigational drug in a new class of RAS inhibitors designed to target a broad spectrum of cancer-causing RAS mutations.

The drug works by blocking KRAS signalling proteins that drive tumor growth.

“It’s been incredibly hard to drug that mutation,” Wolpin said, NBC News reported. “That mutated protein is like a round ball, and you just can’t get the drug to stick to it, to block the effect.” It’s only “through some really amazing chemistry work,” he said, that scientists have been able to develop a drug to work on the mutation.

Daraxonrasib is that first drug. It works by pairing up with a protein called cyclophilin A inside cells, acting like a “molecular glue,” Wolpin said, glomming onto the mutated protein.

Pancreatic cancer is considered one of the most RAS-dependent cancers, with more than 90 per cent of patients carrying tumours driven by RAS protein mutations. Similar RAS-targeting drugs are also being developed for pancreatic, lung and colon cancers.

“It’s the beginning, not the end,” said Elizabeth Jaffee in comments to The New York Times.

The findings was presented at a plenary session of the American Society of Clinical Oncology’s meeting in Chicago on May 31, and simultaneously published in the New England Journal of Medicine.

Read More: Ozempic-Style Drugs May Slowdown Cancer, Study Finds

What Are The Side Effects?

According to the company, “Daxaronrasib was generally well tolerated, with a manageable safety profile and with no new safety signals.”

Previous studies have shown that rash is the most common side effect. Other frequently reported adverse effects include:

• Mouth sores
• Diarrhoea
• Nausea
• Vomiting

FDA Fast-Tracks Daxaronrasib

Based on the first interim analysis, all progression-free survival and overall survival results are now considered final.

Revolution Medicines said it plans to submit the data to global regulators, including the U.S. Food and Drug Administration (FDA), as part of a future New Drug Application under a Commissioner’s National Priority Voucher.

Prime Minister Narendra Modi once again addressed the nation through his monthly radio broadcast, Maan Ki Baat. It was the 134th installment of the broadcast, and the Prime Minister urged the people of India to take extra precautions in summer's scorching heat.

The Prime Minister said, "It is very hot in most parts of the country right now. Strong sun, hot winds, it is very important to take care of yourself in such weather. Keep drinking water. If at all you have to go out in the sun, do so with caution." He added, "Don't forget the guidelines issued by various government departments in this regard."

Then the Prime Minister also addressed traditional food and drinking practices in different parts of the country to stay fit even during the hot summer. He urged the citizens to drink regional traditional drinks to stay hydrated and named popular options like Aam Panna, Sattu sherbet, Kokum sherbet, Sol Kadhi, Panakam, Neer Mor, Sambaram, Bael Pana, and Buttermilk. "Ek Bharat Shreshtha Bharat," he added.

The Prime Minister also mentions mangoes, which are a household summer treat in India. He said, "Every region… its own mango, its own flavor, its own aroma." Then he described these different mangoes and their specialties as well.

Prime Minister Narendra Modi also mentions the journey of the Indian mangoes from domestic production to the global market.

Easy Tips To Stay Fit During a Heatwave

Drink water consistently at regular intervals instead of gulping large quantities at once. Electrolyte-rich fluids like coconut water, lemon water with a pinch of salt, or buttermilk are healthy, affordable options to soothe parched throats.

Add items like curd, rice, cucumber, and bottle gourd to your diet and avoid red meat and fried foods during peak summer days.

Extreme temperatures put additional stress on the cardiovascular system, especially in people with hypertension, diabetes, or heart conditions. Make sure to take all prescribed medications exactly as advised—don’t skip doses even if you experience heat-induced nausea. If you feel dizzy or experience palpitations or severe fatigue, consult your doctor as soon as possible.

Air conditioning is helpful, but overexposure can lead to dry skin, headaches, and respiratory discomfort. Once every two or three hours, step away from your desk for a few minutes. Walk or stand, and sip some water.

The whole world is in terror of Ebola spreading, and countries are on alert. Recently, there has been a possible Ebola-infected person under investigation by the health authorities of Brazil. As per the media reports, the suspected 37-year-old man is admitted to the hospital in São Paulo.

The person with possible Ebola infection is from the Democratic Republic of Congo and started to show Ebola-like symptoms after returning from the African country.

The local health authorities have ensured that he is in isolation, and the hospital specializes in the care of suspected or confirmed cases of the disease.

What Is Ebola?

Ebola is a severe and, in most cases, deadly disease caused by viruses predominantly found in Africa. The spread of the disease happens through contact with infected body fluids.

Some symptoms can indicate a possible infection. This includes fever, weakness, headache, muscle pain, vomiting, diarrhea, sore throat, and unexplained bleeding. This eventually leads to severe complications like bleeding, organ failure, and death. The hosts of the virus are animals like bats, primates, and antelopes.

Why Ebola Spread Is Not Like COVID

The virus is raising serious global health concerns, with Tedros Adhanom Ghebreyesus, WHO Director General, stating that the ongoing Ebola outbreak "is spreading rapidly" and "outpacing us". Yet experts say that it is not COVID and cannot spread like it.

“Ebola does NOT spread through casual airborne exposure like influenza or COVID-19. Individuals become infectious only after symptoms begin, not during the incubation period. The incubation period ranges from 2 to 21 days,” said Dr. Ishwar Gilada, Secretary General, People’s Health Organisation (India).

Experts further explained that Ebola is far more difficult to spread than airborne respiratory viruses such as influenza, COVID-19, measles, and even the Andes strain of hantavirus, which recently caused an outbreak on a cruise ship.

It is because Ebola is not airborne. Ebola does not spread through coughing, sneezing, or casual contact like shaking hands. It spreads only via body fluid contact.

In addition, people with Ebola also do not spread the virus before developing symptoms. This means that during Ebola’s incubation period, which ranges from 2–21 days, an infected person is generally not contagious, unlike COVID-19, where transmission can occur before symptoms appear.